HOLD rating with fair value $0.133 vs current $0.150. Market leader in ANZ adventure tourism with 25% share, EBITDA margins at 14.7%, facing climate and competitive headwinds.
View noteSTRONG SELL rating with 84% downside to $2.20 fair value. EBITDA margins compressing from 26.4% peak as competition intensifies.
View noteQuality gold producer with US$1,075/oz AISC trading at A$4.11 vs A$2.71 fair value. Strong operations, excessive valuation, 34% overvalued.
View noteHOLD rating with $0.56 fair value vs $0.57 current price. Market leader in seniors' rental (18% share, 98% occupancy) executing risky all-age expansion. 35% execution failure probability creates binary outcomes.
View noteFair value $0.65 vs current $0.515. 30% EBITDA margins, 46% ROIC, but 89% international student dependency creates binary regulatory risk.
View notePre-commercial cardiac device company with negative $(0.24) fair value. 77% revenue CAGR offset by permanent -178% EBITDA margins. 75% probability of value destruction versus 25% strategic acquisition hope.
View noteSELL rating with fair value $18.62 vs current $30.24. Healthcare distribution leader faces margin compression and direct distribution threats.
View noteSELL rating with fair value $4.71 vs current $7.42. Office REIT facing structural headwinds from hybrid working, 64% downside risk.
View noteREDUCE rating with $5.50 target vs $9.06 current. Fair value $5.07 implies 44% downside. 71% ROIC, debt-free balance sheet offset by Microsoft dependency and margin compression.
View noteIndustrial cooling manufacturer trading 58% above $2.65 fair value with deteriorating competitive moat, value-destructive ROIC of 7.5% vs 10.5% WACC, and technology disruption risks.
View noteInfrastructure monopoly trading at $4.77 vs $3.11 fair value. 6.0x leverage, 2031 regulatory renewal risk, 91% DCF downside. Quality score 5.1/10.
View noteCyclopharm trades at $0.99 vs $1.18 fair value with 85% global market share in lung imaging, 29% revenue CAGR projected through US expansion
View note